12:00 AM
 | 
Apr 28, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aganirsen: Phase IIa data

A double-blind Phase IIa trial in 12 patients with psoriasis showed that once-daily 0.86 and 1.72 mg/g topical aganirsen each met the primary endpoint of reducing psoriatic lesion size from baseline to week 6 vs. placebo (14.4% and 12.9%, respectively, vs....

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >